Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) vs. Basal-Bolus (BB) Therapy in Patients with Type 2 Diabetes (T2D): DUAL VII Trial

被引：0
|
作者：
Billings, Liana K.
Doshi, Ankur
Gouet, Didier
Oviedo, Alejandra
Rodbard, Helena W.
Tentolouris, Nikolaos
Gron, Randi
Halladin, Natalie
Jodar, Esteban
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
136-OR
引用
收藏
页码：A36 / A36
页数：1
相关论文
共 50 条
  • [41] Basal-bolus insulin regimen is effective for hospitalized patients with type 2 diabetes
    不详
    Nature Clinical Practice Endocrinology & Metabolism, 2007, 3 (12): : 791 - 792
  • [42] Faster-Acting Insulin Aspart vs. Insulin Aspart as Part of Basal-Bolus Therapy Improves Postprandial Glycemic Control in Uncontrolled T2D in the Double- Blinded Onset® 2 Trial
    Bowering, Keith
    Case, Christopher
    Harvey, John
    Reeves, Michael
    Sampson, Mike
    Strzinek, Robert
    Bretler, Ditte-Marie
    Bang, Rikke Beck
    Bode, Bruce W.
    DIABETES, 2016, 65 : A63 - A63
  • [43] Efficacy of Insulin Degludec as Basal-Bolus Therapy After Switching from Insulin Glargine or Insulin Detemir in Young Persons with Type 1 Diabetes
    Urakami, Tatsuhiko
    Habu, Masako
    Okuno, Misako
    Suzuki, Junichi
    Takahashi, Shori
    DIABETES, 2014, 63 : A323 - A323
  • [44] Insulin Degludec/Liraglutide (IDegLira) Improves Patient-Reported Impacts in Subjects with Type 2 Diabetes (T2D) Inadequately Controlled on Insulin Glargine (IG) plus Metformin (Met): DUAL V Study
    Brod, Meryl
    Manghi, Federico C. Perez
    Garcia-Hernandez, Pedro A.
    Norwood, Paul
    Jarlov, Henrik
    Kongso, Jens Harald
    Lingvay, Ildiko
    DIABETES, 2015, 64 : A644 - A644
  • [45] IDegLira Improves Glycemic Control in Japanese Patients with Type 2 Diabetes (T2D) Uncontrolled on Premixed Insulin Therapy
    Watada, Hirotaka
    Agner, Bue F.
    Doshi, Ankur
    Gron, Randi
    Ranthe, Mattis F.
    Billings, Liana K.
    DIABETES, 2019, 68
  • [46] Efficacy and Safety of a Basal-Bolus Regimen of Basal Insulin Plus Insulin Glulisine in Patients With Type 2 Diabetes: A Pooled Analysis of 5 Clinical Trials
    Dailey, George
    Lin, Jay
    Wang, Edward
    DIABETES, 2012, 61 : A284 - A284
  • [47] Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients with Type 2 Diabetes Receiving Basal-Bolus Therapy
    Langer, Jakob
    Wolden, Michael L.
    Shimoda, Seiya
    Sato, Miki
    Araki, Eiichi
    DIABETES THERAPY, 2019, 10 (04) : 1347 - 1356
  • [48] Stepwise intensification of prandial insulin versus basal-bolus insulin therapy in patients with type 2 diabetes mellitus
    Raccah, D.
    Haak, T.
    Huet, D.
    Monnier, L.
    Ramon, J. S.
    Robertson, D.
    Labard, P.
    Penfornis, A.
    DIABETOLOGIA, 2010, 53
  • [49] Insulin aspart vs. regular human insulin in basal/bolus therapy for patients with gestational diabetes mellitus: safety and efficacy
    Jovanovic, L
    Howard, C
    Pettitt, D
    Zisser, H
    Ospina, P
    DIABETOLOGIA, 2005, 48 : A317 - A318
  • [50] Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin
    Vilsboll, Tina
    Blevins, Thomas C.
    Jodar, Esteban
    Poulter, Neil
    Tentolouris, Nikolaos
    Agner, Bue F. Ross
    Lehmann, Lucine
    Leiter, Lawrence A.
    DIABETES OBESITY & METABOLISM, 2019, 21 (06): : 1506 - 1512
12345